An update on prostate cancer

Current Opinion in Oncology

Volumn 13, Issue 3, 2001, Pages 204-211

  Rini, Brian I ^a   Small, Eric J ^b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BICALUTAMIDE; FLUTAMIDE; HYDROCORTISONE; PROSTATE SPECIFIC ANTIGEN; SILDENAFIL; SURAMIN;

BRACHYTHERAPY; CANCER LOCALIZATION; CANCER STAGING; HUMAN; MALE; MENTAL DISEASE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; REVIEW; SCORING SYSTEM; SEXUAL DYSFUNCTION; TUMOR BIOPSY;

HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 0035036561     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200105000-00013     Document Type: Review

References (46)

1. 1 Norrish AE, Skeaff CM, Arribas GL, et al.: Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case-control study. Br J Cancer 1999, 81:1238-1242.
2. 2 Cook NR, Stampfer MJ, Ma J, et al.: Beta-carotene supplementation for patients with low baseline levels and decreased risks of total and prostate carcinoma. Cancer 1999, 86:1783-1792.
3. 3 Sebo TJ, Bock BJ, Cheville JC, et al.: The percent of cores positive for cancer in prostate needle biopsy specimens Is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol 2000, 163:174-178.
4. 4 D'Amico AV, Whittington R, Malkowicz SB, et al.: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974.
5. 5 D'Amico AV, Whittington R, Malkowicz SB, et al.: Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 2000, 18:1164-1172. This study is an important study testing the hypothesis that the percentage of positive prostate biopsies provides clinically relevant information about early biochemical failure after radical prostatectomy. In this study, controlling for known prognostic factors, the percentage of positive biopsy samples was an independent predictor of time to PSA failure and was particularly useful in an intermediate-risk group of patients.
6. 6 Kupelian PA, Mohan DS, Lyons J, et al.: Higher than standard radiation doses (≥ 72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 2000, 46:567-574. This is an important retrospective analysis of 1041 consecutive localized prostate cancer cases treated with external beam radiotherapy. These preliminary data suggest that patients receiving radiation doses exceeding 72 Gy had significantly better PSA progression-free survival.
7. 7 Lyons JA, Kupelian PA, Mohan DS, et al.: Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. Urology 2000, 55:85-90.
8. 8 D'Amico AV, Schultz D, Loffredo M, et al.: Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA 2000, 284:1280-1283. This article is another retrospective study that nevertheless suggests that the addition of 6 months of androgen deprivation to conformal beam radiotherapy improved 5-year biochemical outcome in groups of intermediate-and high-risk patients but not in low-risk patients.
9. 9 Bolla M, Gonzalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997, 337:295-300.
10. 10 Potters L, Torre T, Ashley R, et al.: Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol 2000, 18:1187-1192. This article is a retrospective study of 612 patients treated with brachytherapy with or without androgen deprivation. With short follow-up at 5 years, the PSA relapse-free survival rate was not improved with the addition of androgen deprivation to brachytherapy. No subset was found for which the addition of androgen deprivation was beneficial.
11. 11 Zelefsky MJ, Leibel SA, Kutcher GJ, et al.: Three-dimensional conformal radiotherapy and dose escalation: where do we stand? Semin Radiat Oncol 1998, 8:107-114.
12. 12 Kestin LL, Martinez AA, Stromberg JS, et al.: Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer. J Clin Oncol 2000, 18:2889-2880.
13. 182Iridium prostate brachytherapy: feasibility report. Int J Radiat Oncol Biol Phys 1998, 41:525-533.
14. 14 Weber DC, Bieri S, Kurtz JM, et al.: Prospective pilot study of sildenafil for treatment of postradiotherapy erectile dysfunction in patients with prostate cancer. J Clin Oncol 1999, 17:3444-3449.
15. 15 Kedia S, Zippe CD, Agarwal A, et al.: Treatment of erectile dysfunction with sildenafil citrate (Viagra) after radiation therapy for prostate cancer. Urology 1999, 54:308-312.
16. 16 Zelefsky MJ, McKee AB, Lee H, et al.: Efficacy of oral sildenafil in patients with erectile dysfunction after radiotherapy for carcinoma of the prostate. Urology 1999, 53:775-778.
17. 17 Merrick GS, Butler WM, Lief JH, et al.: Efficacy of sildenafil citrate in prostate brachytherapy patients with erectile dysfunction. Urology 1999, 53:1112-1116.
18. 18 Lowentritt BH, Scardino PT, Miles BJ, et al.: Sildenafil citrate after radical retropubic prostatectomy. J Urol 1999, 162:1614-1617.
19. 19 The Medical Research Council Prostate Cancer Working Party Investigators Group: Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997, 79:235-246.
20. 20 Messing EM, Manola J, Sarosdy M, et al.: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999, 341:1781-1788.
21. 21 Herr HW, O'Sullivan M: Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 2000, 163:1743-1746. This article is a longitudinal evaluation of quality of life in patients treated with androgen deprivation therapy. It is an important study that quantifies what many physicians already know: androgen deprivation may significantly impair the physical and emotional health of otherwise asymptomatic patients with nonmetastatic prostate cancer.
22. 22 Iversen P, Tyrrell CJ, Kaisary AV, et al.: Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow-up. J Urol 2000, 164:1579-1582.
23. 23 Boccardo F, Rubagotti A, Barichello M, et al.: Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol 1999, 17:2027-2038. This study is one of two studies that suggest that monotherapy with high-dose bicalutamide is equivalent to combined androgen blockade. Quality of life measures favored the monotherapy group. Although there are problems with methodologic flaws, imbalances in the treatment arms, and short follow-up, these data are nevertheless provocative.
24. 24 Daniell HW, Dunn SR, Ferguson DW, et al.: Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000, 163:181-186. This important study measured bone marrow density loss in men undergoing androgen deprivation. Although the study did not correlate this bone mineral loss with the likelihood of osteoporotio fractures, it clearly identifies a growing area of interest.
25. 25 Pisansky TM, Kozelsky TF, Myers RP, et al.: Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol 2000, 163:845-850.
26. 26 Cadeddu JA, Partin AW, DeWeese TL, et al.: Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 1998, 159:173-178.
27. 27 Crane CH, Rich TA, Read PW, et al.: Pre-irradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation. Int J Radiat Oncol Biol Phys 1997, 39:681-686.
28. 28 de la Taille A, Hayek O, Benson MC, et al.: Salvage cryotherapy for recurrent prostate cancer after radiation therapy: the Columbia experience. Urology 2000, 55:79-84.
29. 29 Prostate Cancer Trialists' Collaborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000, 355:1491-1498. This study is another meta-analysis of randomized trials comparing combined androgen blòckade versus monotherapy with gonadal androgen ablation. It has successfully collected and tabulated data from all clinical trials conducted in this area.
30. 30 Hussain M, Fisher EI, Petrylak DP, et al.: Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: a Southwest Oncology Group Study. J Clin Oncol 2000, 18:1043-1049.
31. 31 Dawson NA, Figg WD, Cooper MR, et al.: Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. J Clin Oncol 1997, 15:1470-1477.
32. 32 de Reijke TM, Keuppens FI, Whelan P, et al.: Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group Trial. J Urol 1999, 162:1658-1664.
33. 33 de la Taille A, Hayek OR, Buttyan R, et al.: Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and patients. BJU Int 1999, 84:845-850.
34. 34 de la Taille A, Buttyan R, Hayek O, et al.: Herbal therapy PC-SPES: in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. J Urol 2000, 84:845-850.
35. 35 Pfeifer BL, Pirani JF, Hamann SR, et al.: PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer. BJU Int 2000, 85:481-485.
36. 36 Small EJ, Frohlich MW, Bok R, et al.: Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 2000, 18:3595-3603. This prospective trial of the herbal supplement PC-SPES points out that this agent appears to have some antiprostate cancer activity and, importantly, tabulates toxicity profile.
37. 37 Rafi MM, Rosen RT, Vassil A, et al.: Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid. Anticancer Res 2000, 20:2653-2658.
38. 38 Hsieh TC, Ng C, Chang CC, et al.: Induction of apoptosis and down-regulation of bcl-6 in mutu I cells treated with ethanolic extracts of the Chinese herbal supplement PC-SPES. Int J Oncol 1998, 13:1199-1202.
39. 39 Small EJ, Meyer M, Marshall ME, et al.: Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 2000, 18:1440-1450.
40. 40 Tannock IF, Osoba D, Stockler MR, et al.: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996, 14:1756-1764.
41. 41 Bracarda S, Tonato M, Rosi P, et al.: Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study. Cancer 2000, 88:1438-1444.
42. 42 van Brussel JP, Busstra MB, Lang MS, et al.: A phase II study of temozolomide in hormone-refractory prostate cancer. Cancer Chemother Pharmacol 2000, 45:509-512.
43. 43 Fields-Jones S, Koletsky A, Wilding G, et al.: Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial. Ann Oncol 1999, 10:1307-1310.
44. 44 Blasko JC, Grimm PD, Sylvester JE, et al.: Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000, 46:839-850. This study reports on 230 good-risk prostate cancer patients treated with palladium brachytherapy. The overall biochemical progression-free survival rate at 9 years was 83.5%. these are encouraging data, which are approaching sufficient maturity.
45. 45 Zelefsky MJ, Hollister T, Raben A, et al.: Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2000, 47:1261-1266.
46. 46 Brachman DG, Thomas T, Hilbe J, et al.: Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys 2000, 48:111-117. This retrospective study reviewed 1527 patients treated with external beam radiotherapy and 695 patients trealed with brachytherapy. In these good-risk groups of patients with relatively short follow-up, the failure-free survival rate at 5 years was identical, at approximalely 70%. A subset analysis suggests that external beam radiotherapy was superior for high-risk patients, defined by high Gleason score or high PSA value.